Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

Why did oil prices surge after Israel attacked Iran? How did Israel's strike impact global stock markets? What caused Walmart and Amazon to explore stablecoins? Why was Senator Alex Padilla forcibly removed in LA? How will the Air India crash affect Boeing's stock? What are the implications of Meta’s Scale AI investment? Why is consumer sentiment improving despite inflation concerns?

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

benzinga.com/analyst-stock-ratings/initiation/25/06/45913266/recently-listed-tvardi-therapeutics-lead-drug-positioned-to-drive-broad-improvem

Newly public Tvardi Therapeutics, Inc. (NASDAQ:TVRD) is capturing investor attention following its recent reverse merger with Cara Therapeutics, Inc.
In April, the company completed its previously announced merger with Cara Therapeutics. Tvardi is a clinical-stage biopharmaceutical…

This story appeared on benzinga.com, 2025-06-12 19:08:05.